Sugi Predict

Sugi Predict / Compounds / SCHEMBL207935

SCHEMBL207935

SCHEMBL207935

O=Cc1ccc(Br)cc1OC(F)(F)F

nearest known ligand 0.52

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ MAOA P21397 1/20 0.52
▸ MAOB P27338 1/20 0.52
▸ ERN1 O75460 2/20 0.43
▸ PTGDR2 Q9Y5Y4 1/20 0.41
▸ ALPL P05186 3/20 0.39
▸ CYP2A6 P11509 2/20 0.38
▸ ALDH1A1 P00352 2/20 0.37
▸ HRH4 Q9H3N8 1/20 0.35
▸ PTPN1 P18031 2/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ PRKDC P78527 1/20 0.34
▸ EPHX2 P34913 1/20 0.33
▸ ADRA2A P08913 1/20 0.33
▸ NPY5R Q15761 1/20 0.33
▸ MCHR1 Q99705 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29377196 0.86 PTGDR2 (0.51) MAOAMAOBERN1PTGDR2ALPL
SCHEMBL408055 0.86 PTGDR2 (0.51) MAOAMAOBERN1PTGDR2ALPL
SCHEMBL9242228 0.85 TRPV1 (0.42) MAOAMAOBERN1PTGDR2CYP2A6
SCHEMBL13581108 0.84 MAOA (0.41) MAOAMAOBERN1PTGDR2ALDH1A1
SCHEMBL1220795 0.80 ALDH1A1 (0.40) MAOAMAOBERN1ALDH1A1HRH4
SCHEMBL29953626 0.79 ALDH1A1 (0.37) MAOAMAOBALDH1A1L3MBTL1EPHX2
SCHEMBL8224315 0.79 ALDH1A1 (0.41) MAOAMAOBERN1CYP2A6ALDH1A1
SCHEMBL15534680 0.79 APP (0.42) MAOAMAOBERN1ALDH1A1L3MBTL1
SCHEMBL7088703 0.79 TDP1 (0.50) MAOAMAOBERN1ALPLALDH1A1
SCHEMBL17376673 0.78 APP (0.44) MAOAMAOBERN1PTGDR2CYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 245 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12590062-B2 PD-1/PD-L1 inhibitors GILEAD SCIENCES, INC. (US) 2026-03-31 — — US disclosed
WO-2025224085-A1 COMPOUNDS CAPABLE OF ACTING ON S1R AS WELL AS ON SEH AND USES THEREOF UNIVERSITAT DE BARCELONA (ES) 2025-10-30 — — WO disclosed
EP-4618985-A1 DUAL INHIBITORS OF SIGMA-1 RECEPTOR AND SOLUBLE EPOXIDE HYDROLASE AND THEIR USE IN THE TREATMENT OF PAIN Universitat De Barcelona (ES) 2025-09-24 — — EP disclosed
US-20250262205-A1 DUAL MAGL AND FAAH INHIBITORS LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) 2025-08-21 — — US disclosed
US-12318383-B2 Dual MAGL and FAAH inhibitors LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) 2025-06-03 — — US disclosed
CN-119823124-A Compounds for targeted degradation of BRD9 C4医药公司 2025-04-15 — — CN disclosed
CN-117736178-B Dual MAGL and FAAH inhibitors 灵北拉荷亚研究中心公司 2025-03-21 — — CN disclosed
US-20250084081-A1 COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 C4 THERAPEUTICS, INC. (US) 2025-03-13 — — US disclosed
CN-115279370-B Compounds for targeted degradation of BRD9 C4医药公司 2025-01-10 — — CN disclosed
US-12157735-B2 Compounds for targeted degradation of BRD9 C4 THERAPEUTICS, INC. (US) 2024-12-03 — — US disclosed
WO-2005095357-A2 PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF TAISHO PHARMACEUTICAL CO., LTD. (JP) 2005-10-13 — — WO disclosed
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof TAISHO PHARMACEUTICAL CO., LTD. 2005-09-08 — — US disclosed
CN-1582281-A MCH receptor antagonists TAISHO PHARMACEUTICAL CO LTD (JP) 2005-02-16 — — CN disclosed
WO-2004087680-A1 NOVEL QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF TAISHO PHARMACEUTICAL CO., LTD. (JP) 2004-10-14 — — WO disclosed
WO-2004087669-A1 NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF TAISHO PHARMACEUTICAL CO. LTD. (JP) 2004-10-14 — — WO disclosed
EP-1464335-A2 Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist Taisho Pharmaceutical Co. Ltd. (JP) 2004-10-06 — — EP disclosed
EP-1432693-A2 MCH RECEPTOR ANTAGONISTS Taisho Pharmaceutical Co. Ltd. (JP) 2004-06-30 — — EP disclosed
WO-2003028641-A2 MCH RECEPTOR ANTAGONISTS TAISHO PHARMACEUTICAL CO., LTD. (JP) 2003-04-10 — — WO disclosed
US-6090805-A Tocolytic oxytocin receptor antagonists MERCK & CO., INC. (US) 2000-07-18 — — US disclosed
US-5968938-A Piperazine oxytocin receptor antagonists MERCK & CO., INC. (US) 1999-10-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250262205-A1 DUAL MAGL AND FAAH INHIBITORS FAAH, FAAH2, MAG MAOA 64/4885MAOB 46/4885ERN1 3423/4885
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof HCRTR2, MCHR1, MCHR2 MAOA 272/4885MAOB 168/4885ERN1 3661/4885
US-12318383-B2 Dual MAGL and FAAH inhibitors FAAH, FAAH2, MAG MAOA 64/4885MAOB 46/4885ERN1 3423/4885
US-12157735-B2 Compounds for targeted degradation of BRD9 BRD9, BRD1, BRWD1 MAOA 4618/4885MAOB 4433/4885ERN1 1469/4885
US-12590062-B2 PD-1/PD-L1 inhibitors CD274, PDCD1LG2, PDCD1 MAOA 1365/4885MAOB 1633/4885ERN1 1934/4885
US-20250084081-A1 COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 BRD9, BRD1, BRWD1 MAOA 4618/4885MAOB 4433/4885ERN1 1469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.